Through this partnership, Svar Life Science will help clients access Lablytica's GLP-certified LC-MS/MS services, which are essential for pharmacokinetics (PK), pharmacodynamics (PD), biomarker quantification, and therapeutic drug monitoring across all phases of drug development, from discovery to clinical trials.

"This partnership marks a major milestone in our mission to provide end-to-end, science-driven bioanalytical solutions," said Anna Karaszewska, Product Manager, CRO Services at Svar Life Science. "By joining forces with Lablytica, we are expanding our capabilities to meet the growing demand for high-sensitivity, high-specificity analysis of complex biologics and small molecules. It's a strategic move that strengthens our position in the European CRO landscape and reinforces our commitment to scientific excellence."

Lablytica, based in Uppsala, Sweden, operates as a stand-alone CRO and brings over a decade of expertise in regulated bioanalysis. Their services include method development, validation, and sample analysis using state-of-the-art LC-MS/MS platforms, fully compliant with FDA, EMA, and ICH M10 guidelines.

"We are excited to partner with Svar Life Science to broaden the reach of our services," said David Pekar, CEO of Lablytica. "Together, we can offer clients a seamless and integrated bioanalytical experience, tailored to the evolving needs of modern drug development."

Key Benefits of the Partnership:

• Expanded Service Offering: Integration of LC-MS/MS with Svar's existing ligand-binding and cell-based assay platforms.
• Regulatory Strength: Full GLP and GCP compliance across all analytical services.
• Therapeutic Versatility: Support for small molecules, biologics, antibody-drug conjugates (ADCs), peptides, oligonucleotides, and more.
• Client-Centric Collaboration: A shared commitment to scientific partnership, transparency, and tailored project support.
• Market Reach: Enhanced access to biotech, pharma, and CRO clients across Europe.

This collaboration positions Svar Life Science as a bioanalytical integration partner, delivering flexible, high-quality solutions for complex therapeutic programs. The partnership is part of Svar's broader strategy to drive innovation, expand market presence, and support the development of next-generation therapies.